Close menu

February 8th, 2021 | 07:30 CET

Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

  • Health
Photo credits:

Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

time to read: 2 minutes | Author: Nico Popp
ISIN: SG2E73981531 , DE0005785604 , DE0005785802

Table of contents:

    Fresenius or Fresenius Medical Care?

    If you're a casual investor looking at the price lists of German stocks, you're bound to notice Fresenius and Fresenius Medical Care. But what do these two companies do? In a nutshell, Fresenius is the parent Company and has a stake in Fresenius Medical Care. While Fresenius also operates hospitals and offers other products, such as infusions or nutrition, Fresenius Medical Care focuses entirely on dialysis. This form of blood washing helps patients with weak kidneys stay healthy and buy time until the kidneys can resume their function or a donor kidney can be transplanted. In addition to dialysis as a service, Fresenius Medical Care also offers dialysis products.

    Even though the parent Company Fresenius profits about 50% from the dialysis business, the specialized subsidiary is more promising on the stock market. While Fresenius Medical Care effectively occupies a niche and can profit from trends such as aging society in the long term, Fresenius has to contend with hospital services and infusion. These two business segments are not doing well at the moment. During the peak phase of the pandemic, postponed surgery appointments also had a negative impact.

    Fresenius Medical Care: Interesting at the three-year low despite everything

    Comparing the shares of Fresenius and Fresenius Medical Care, the parent Company currently looks more favorably valued. Since Fresenius also has a stake of around 50% in the strong dialysis subsidiary, the share, which is considered boring, is worth considering for long-term investors. The services and infusion business has weakened recently, but this can be remedied. In the long term, Fresenius should be able to benefit from rising spending in the healthcare sector. Fresenius Medical Care recently shocked the market with a weak earnings forecast for 2021, which sent the stock on a downward slide close to its three-year low. However, those who take a long-term view can analyze this stock in more detail.

    Q & M Dental: Asia invests in beautiful teeth

    A share that is hardly known in Germany but has an attractive business model is Q & M Dental. The operator of 114 dental practices, five clinics and three distribution companies for medical products in Singapore, Malaysia and China already made a virtue out of necessity in the summer of 2020 and invested in a corona tests manufacturer. While the government supported the Company because of the collapsed business with dental treatments, Q&M pushed test procedures and is now a licensed partner of the Ministry of Health in Singapore for corona tests.

    The go-getting management team also has its sights set on other regions of the world. Since Q & M Dental had already planned to expand even more in China and Malaysia before the pandemic, it has growth potential. A study by KGI, an Asian analyst firm, gave the stock a potential upside of nearly 20% at the end of November. Given Q & M's stable business in Singapore, the side earnings with Corona tests, and the expansion fantasy, the stock could be a welcome alternative for investors who find Asian healthcare stocks exciting.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST

    Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

    • Biotechnology
    • Covid19
    • Health

    Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...


    Commented by Nico Popp on November 25th, 2021 | 11:46 CET

    BB Biotech, Sativa Wellness, Carnival: Anti-aging as a megatrend

    • Health

    Anti-aging medicine is one of the most exciting research topics of our time. Already in 2018, Citigroup named the field as one of the ten rising topics of the future. While the pandemic has obscured many long-term ventures in the media, the work continues. People have long been optimizing and working to feel at least a little younger. We present three stocks related to biotechnology, anti-aging and wellness.


    Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET

    CureVac, Cardiol Therapeutics, Bayer - roaring profits!

    • Health

    The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.